Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

NCT02430363 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

58

Enrollment

OTHER_GOV

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: MK - 3475
BIOLOGICAL: Suppressor of the PI3K/Akt pathways

Sponsor

Medical Research Council

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]